Gunendi, ZaferYurdakul, Fatma GülBodur, HaticeCengiz, Ahmet KivancUçar, ÜlküCay, Hasan FatihAtaman, ŞebnemNayimoğlu, MehmetSarıfakıoğlu, Ayşe Banu2022-05-112022-05-1120210172-81721437-160Xhttps://doi.org/10.1007/s00296-021-04892-6https://hdl.handle.net/20.500.11776/8705The study aimed to evaluate the impact of the coronavirus disease 2019 (COVID-19) in patients with familial Mediterranean fever (FMF) and to assess the relationships between FMF characteristics and severe COVID-19 outcomes such as hospitalization. The study was planned within a national network of 21 different centers. Demographics, FMF-related clinical and genetic characteristics, and COVID-19 outcomes were obtained. A total of 822 patients with FMF (mean age of 36 years) were included in the study. Fifty-nine of them (7%) had a COVID-19 diagnosis confirmed by real-time PCR test or chest CT findings. Most FMF patients with COVID-19 (58) had mild and moderate disease activity. All patients were on colchicine treatment. However, 8 of them (13.6%) were not compliant with colchicine use and 9 of them (15.3%) were colchicine resistant. Twelve FMF patients with COVID-19 were hospitalized. There were 4 patients requiring oxygen support. COVID-19 related complications were observed in 2 patients (1 thromboembolism, 1 acute respiratory distress syndrome). Hospitalized COVID-19 patients with FMF were older than non-hospitalized patients (median ages: 51 and 31 years, respectively; p: 0.002). Other FMF-related characteristics were similar between the groups. FMF-related characteristics were not found to be associated with poor outcomes in COVID-19. Thus, FMF may not be a risk factor for poor COVID-19 outcomes.en10.1007/s00296-021-04892-6info:eu-repo/semantics/openAccessCOVID-19Familial Mediterranean feverRheumatic diseasesColchicineHospitalizationPoor outcomesArticle41814471455Q3WOS:0006540891000022-s2.0-8510646398334032894Q2